
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc demonstrates a positive outlook driven by strong clinical data from its pipeline products, particularly icotrokinra, which has shown significant improvements in clinical response and endoscopic outcomes over time. The strong business development track record and anticipated momentum from upcoming catalysts further enhance the company's growth potential, particularly as icotrokinra is poised to fill a market gap left by existing therapies. As the company prepares for a New Drug Application (NDA) submission for icotrokinra in July 2025, the promising efficacy and safety results position Protagonist Therapeutics favorably within the biopharmaceutical landscape.
Bears say
Protagonist Therapeutics faces significant risks that contribute to a negative outlook, primarily due to potential safety concerns arising from ongoing clinical trials, which could adversely affect its product development. The company also encounters competitive challenges that might lead to strategic partners deciding against further development of its lead candidate, Icotrokinra, as well as heightened regulatory and pricing risks that could impact market viability. Additionally, the ongoing need for future capital, combined with the risk of dilution for existing shareholders, presents financial uncertainties that could hinder the company’s operational stability.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares